Exploitation of transporters to develop novel antimicrobials against Gram-negative bacteria

利用转运蛋白开发针对革兰氏阴性菌的新型抗菌药物

• 批准号: 102856
• 金额: $ 133.79万
• 依托单位: DISCUVA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102856
• 关键词: Exploitation; transporters; develop; novel; antimicrobials

We need new classes of antibiotics because multi-drug resistant (MDR) bacteria are threatening our ability to treat infectious disease. The UK government estimates that without new antibiotics infectious disease will cost the global economy $100 trillion by 2050. Discuva’s innovative (and proprietary) technology (SATIN) is a proven platform for the discovery of new antibiotics; SATIN has already delivered new antibacterial compounds with novel mechanisms-of-action and within our lead programme clinical trials are planned in 2017 for the treatment of MDR gonorrhoea. This project will use this UK invented technology to deliver improved antibiotics which are both highly active against some of the most resistant bacteria causing disease and have a reduced likelihood of selecting resistance compared to conventional antibiotics. This will address the issue of clinical failure associated with the most resistant and life-threatening bacterial infections including E. coli. Ultimately, this project has potential for significant benefits to patients, the NHS (and health care systems globally), and the antibiotc research community.

我们需要新型抗生素，因为多重耐药 (MDR) 细菌正在威胁我们治疗传染病的能力。英国政府估计，如果没有新的抗生素，到 2050 年，传染病将给全球经济造成 100 万亿美元的损失。Discuva 的创新（专有）技术 (SATIN) 是发现新抗生素的经过验证的平台； SATIN 已经提供了具有新颖作用机制的新型抗菌化合物，在我们的主导项目中，计划于 2017 年进行治疗耐多药淋病的临床试验。该项目将使用这项英国发明的技术来提供改进的抗生素，这些抗生素对一些引起疾病的最具耐药性的细菌具有高度活性，并且与传统抗生素相比，选择耐药性的可能性更低。这将解决与包括大肠杆菌在内的最具耐药性和威胁生命的细菌感染相关的临床失败问题。最终，该项目有可能为患者、NHS（以及全球医疗保健系统）和抗生素研究界带来重大利益。